Tag: Vivos

LITTLETON, Colo. – Vivos Therapeutics, a medical technology company focused on developing treatments for patients suffering from mild-to-moderate obstructive sleep apnea and snoring in adults, announced that its flagship daytime-nighttime appliance (DNA) will be tested in a clinical trial at Stanford Medicine. “We are extremely excited to be starting this trial at Stanford Medicine, which has been in the works for some time” said R. Kirk Huntsman, chairman and CEO of Vivos. “I...

LITTLETON, Colo. – Vivos Therapeutics, Inc., a medical technology company focused on developing treatments for patients suffering from mild-to-moderate obstructive sleep apnea, has closed its previously announced private placement offering with a single institutional investor for $8 million in gross proceeds. After the placement agent fees and estimated offering expenses, the company expects to receive net proceeds of approximately $7.4 million, which it intends to use for general working capital...

LITTLETON, Colo. - Vivos Therapeutics, a medtech company focused on developing innovative treatments for patients suffering from obstructive sleep apnea, has received clearance from the U.S. Food and Drug Administration for its proprietary daytime-nighttime (DNA) appliance. With FDA clearance, the DNA appliance offers a new treatment regimen that opens the airway by expanding the palate and training the tongue to rest in the proper position, converting patients to nasal as opposed to oral breathing. ...

HIGHLANDS RANCH, Colo. – Vivos Therapeutics saw an 18-times increase in the total number of SleepImage Home Sleep Apnea Tests given across its network of trained dentists (known as Vivos Integrated Practices or VIPs) for the three months ended Dec. 31, 2021. The company also reported a 5.7-times increase in the number of VIPs administering HSTs; and a 3-times increase in the average number of HSTs being administered per VIP. “We have always believed that the pathway to getting more patients...